Liver Disease Flashcards

1
Q

Variables in Child Pugh Score

A

Encephalopathy
Ascites
Bilirubin
Albumin
Prothrombin time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Child Pugh A, B, C

A

A= 5-6 points
B = 7-9 points
C >10 points

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Ascites treatment

A

1) Treat cause of cirrhosis
2) Na restriction <2000mg/day; fluid restriction <1.5L/day
3) Spironolactone 100mg (initial)
4) Add furosemide 40mg for subsequent. Titrate q3 days to max of 400/160mg
5) Large volume paracentesis with albumin replacement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Meds to avoid with ascites

A

NSAIDs
ARB
ACE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Hepatic encephalopathy classical physical finding

A

asterixis “hand flap”
If present = Grade II (overt) on West Haven

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Lactulose

A

Converts ammonia to ammonium in gut which cannot be absorbed

DOC for overt hepatic encephalopathy

May be given as an enema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Antibiotcs for hepatic encephalopathy

A

Neomycin = as effective as lactulose, caution renal insufficiency

Metronidazole = caution, long term use can cause peripheral neuropathy

Rifaximin = as effective as lactulose; better tolerated than neomycin but expensive. May add on to lactulose therapy if subsequent episode.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Flumazenil concern

A

lowering seizure threshold if benzo overdose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Esophageal varices bleed management

A

1) Fluid resuscitation. FFP or platelets if needed to maintain Hgb >8
2) Endoscopy +/- sclerotherapy
3) Ocretotide preferred over vasopressin + nitroglycerin
4) Ceftriaxone 1g x7d or FQ = reduces short term mortality

Endoscope + Octreotide is preferred medical management option

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Primary prophylaxis for varices

A

-Only if medium to large varices and no history of bleeding

Nonselective beta blockers (propranolol, nadolol, carvedilol)
Blocks B1 (reduce cardiac output) and B2 (prevent splanchnic vasodilation). Unopposed alpha1 constriction of splanchnic circulation leads to reduction in portal pressure

**Goal: resting HR 55-60bpm for 25% reduction

do not use long acting nitrates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Secondary prophylaxis for varices

A

ALL PATIENTS WITH HISTORY OF VARICEAL BLEED SHOULD RECEIVE SECONDARY PPX

Combination of:
1) endoscopic variceal band ligation
2) nonselective B blocker (carvedilol, propranolol, nadolol)

May combine BB with long acting nitrate, but increased risk of side effects; no mortality benefit

shunt is reserved for medically unresponsive pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Antibiotic for CA-SBP

A

Ceftriaxone or cefotaxime x5-7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Antibiotic for Nosocomial SBP or risk for MDRO

A

Zosyn +/- Daptomycin (if prior infection or VRE-+)

OR

Meropenem (if recent Zosyn exposure or known MDRO) +/- Vanco or teicoplanin (if MRSA risk)

5-7 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Lab values in SBP

A

Elevated SCr or leukocytosis

MUST PEROFRM PARACENTESIS PRIOR TO FIRST ANTIBIOTIC DOSE

> 250 PMNs = diagnostic for SBP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Albumin replacement for SBP

A

SBP exacerbates intravascular hypovolemia & organ hypoperfusion that is present with cirrhosis

Albumin 1.5g/kg on admission & 1g/kg on day 3 improves survival, especially if jaundiced or AKI

RECOMMENDED IN THESE PTS:
SCr >1 or
BUN>30 or
Total bili >5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

SBP Prophylaxis

A

Cipro 500mg daily
Bactrim DS daily

Continue indefinitely

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Hepatorenal Syndrome

A

Cirrhosis + ascities + AKI
SCr increase 0.3 in 48 hours or 50% inc in SCr in 7 days
No response to diuretic withdrawal and albumin infusion

AKI cannot be due to structural kidney issue or nephrotoxic meds

Give Vasoconstrictor therapy (norepi) + albumin

18
Q

Maddrey discriminant function score

A

4.6 * (PT - control PT) + total bili

> 32 = poor prognosis

19
Q

Alcoholic liver disease therapy

A

If Maddrey score >32 or MELD >20 =

Prednisolone 40mg/day for 4 weeks, then 2 week taper
30% decrease in short-term death

IV acetylcysteine plus steroids should be considered

20
Q

Lille score

A

Measures change in bilirubin after 7 days of steroid therapy in alcoholic cirrhosis patients

Determines if prednisolone should continue for full 28 days

21
Q

Hepatitis A transmission

A

Fecal oral
self limiting disease; supportive care; vaccine >1 y/o or high risk groups

22
Q

Hepatitis A Immune Globulin

A

Required for traveling to endemic countries or <1 y/o

23
Q

Hepatitis A post exposure prophylaxis

A

Vaccine ASAP, but within 2 weeks exposure

Immune globulin 0.1ml/kg if cannot receive vaccine

24
Q

Serologic assay for Hepatitis B screening

A

HBV Surface Antigen (HBsAg)
this is the first detectable serum antigen in acute infection but is also present in chronic infection

25
HBeAg
E antigen -- serologic marker that most patients have demonstrates active viral replication
26
Chronic Hepatitis B clinical definition
HBsAg + > 6 mo Serum HBV DNA >20,000 AST/ALT elevation Biopsy demonstrates chronic hepatitis **treat these patients right away. all other cases, can wait to see if spontaneously resolves**
27
Goal of Hepatitis B therapy
LFTs back to normal HBV DNA to undetectable loss of HBeAg if positive If nonresponse then change therapy
28
HBV therapy first line
Entecavir (Baraclutde) 0.5mg TAF (Vemlidy) 25mg TDF (Viread) 300mg If lamivudine resistant, entecavir should be 1mg Use for 1 year
29
Pegylated interferon
Not as effective in HBeAg negative Pegasys 180mcg SC weekly x48 weeks WILL increase ALT. This is expected and not an ADR. May need filgrastim for leukopenia CNS effects, thyroid
30
Typical Hep B vaccine schedule
Three doses (0, 1, 6 mo) Exception: Heplisav-B (0, 1 mo) and Engerix B if on HD (0,1,2,6 mo)
31
Hep B immune globulin
Give within 7 days of exposure (0.06mL/kg) If perinatal transmission, administer first dose within 12 hours of birth (HBsAG+ mom)
32
Hepatitis C goal of therapy
Sustained Virologic Response (SVR) = undetectable HCV RNA 12 weeks after completion of therapy. Considered cured
33
Pre/post exposure prophylaxis for hepatitis C
None recommended
34
HCV preferred treatment for patient without cirrhosis
Glecaprevir + pibrentasvir x8 weeks Sofosbuvir + velpatasvir x12 weeks
35
HCV preferred treatment with compensated cirrhosis (class A)
Glecaprevir + pibrentasvir x8 weeks Sofoxbuvir + velpatasvir x12 weeks for genotypes 1,2,4,5,6 Genotype 3 requires NS5A RAS testing
36
Genotype Ia & Ib HCV treatment
glecaprevir + pibrentasvir (Mavyret) x8week lamivudine/sofosbuvir x12 week velpatasvir + sofosbuvir (Epclusa) x12 weeks Ib also has elbasvir + grazoprevir (zepatier) x 12 weeks
37
Ribavirin ADRs
hemolytic anemia teratogenicity pancreatitis depression (riba rage) pulmonary issues
38
Sofosbuvir notable drug interactions
Statins (combo not recommended) anticonvulsants (carbamazepine, phenytoin, phenobarbital, oxcarbazepine) amiodarone (symptomtic bradycardia) antacids
39
Mavyret (glecaprevir/pibrentasvir) notable drug interactions
pgp 3a4 inducers (carbaamzepine, efavirenz, st johns wort) Atazanavir, rifampin antacids statins
40
Zepatier (grazoprevir/elbasvir) notable drug interactions
OATP1B1/3 inhibitor strong 3A4 inducers efavirenz antacids statins
41
Monitoring for HCV treatment
Baseline: HCV RNA, genotype, CBC, LFT, GFR, HIV, Hepatitis B, pregnancy test While on therapy: adherence, interactions After: HCV RNA 12 weeks after